Baricitinib is an oral, selective inhibitor of Janus kinase (JAK) 1/JAK2 that transiently and
reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a …

JAK inhibitors impact multiple cytokine pathways simultaneously, enabling high efficacy in
treating complex diseases such as cancers and immune-mediated disorders. However, their …

Introduction Autoinflammatory diseases (AID) are rare diseases presenting with episodes of
sterile inflammation. These involve multiple organs and can cause both acute organ …

Janus kinase (JAK) inhibitors have been recently approved by the FDA and are widely used
in the treatment of patients with atopic dermatitis. However, a comprehensive safety profile of …

The JAK-STAT signaling pathway mediates important cellular processes such as immune
response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that …

Abstract Background Baricitinib, a selective Janus kinase (JAK) 1/JAK2 inhibitor, is
approved for treatment of moderate-to-severe atopic dermatitis (AD) in adults. Objectives We …

JAK-STAT cytokines are critical in regulating immunity. Persistent activation of JAK-STAT
signaling pathways by cytokines drives chronic inflammatory diseases such as asthma …

Janus kinase inhibitors (JAKi) have enormous appeal as immune-modulating therapies
across many chronic inflammatory diseases, but recently this promise has been …

Background Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, has shown
encouraging anti-tumour activity in heavily pre-treated patients with relapsed or refractory …

JAK inhibitors (JAKi) are new targeted-synthetic drugs, approved for various immune-
mediated inflammatory diseases (IMIDs), including inflammatory arthritides (rheumatoid …